Overexpression of RAD51 is a predictor of a poor outcome in colorectal adenocarcinoma [28], breast cancer [29], pancreatic cancer [30] and non-small cell lung cancer [31]. This evidence concerns the gene RAD51 and pancreatic neoplasm.